First DCE analysis in age-related wet macular degeneration!

The Ingress-health team recently published the very first discrete-choice based preference analysis in patients with age-related wet macula degeneration. This technique had not been used so far in this disease, so this is the first worldwide publication in this respect. It is published in the high-impact ophthalmology journal “Ophthalmology”. The results of the analysis show

Lees meer

Non-persistence/non-adherence in T2DM patients; insights from UK and Germany real-world setting

In our recently published work, we have utilized data from two large retrospective datasets: a German claims dataset and the UK General Practitioner (GP)-based Clinical Practice Research Datalink (CPRD) dataset (2010–2012). The study included 1,905 and 1,627 type 2 diabetes mellitus (T2DM) patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists from the UK and Germany, respectively.

Lees meer

What risk factors are associated with UTI in T2DM patients?

Insights from a real-world setting, 456,586 T2DM German patients. In our recently published work we investigated urinary tract infection (UTI) incidence among Type 2 Diabetes mellitus (T2DM) patients in Germany. Moreover, we aimed to identify risk factors associated with UTI incidence/recurrence. A total of 456,586 T2DM- patients were identified. Overall, the UTI event rate was

Lees meer

Meet us at ISPOR Milan 2015

The ISPOR 18th Annual European Congress that will be held in Milan this year, 7-11 November 2015, is almost there. We, Ingress-Health, are having a booth this year: stand No. 1010. Visit us for a little chat! In addition to several poster presentations, Ingress-Health is organizing a workshop titled “Availability, strengths and limitations of real-world

Lees meer

Meet us at 51st European Association for the Study of Diabetes (EASD) Annual Meeting

The 51st (EASD) Annual Meeting is taking place at Stockholm, Sweden, 14-18 September 2015. Prof. Thomas Wilke will be giving an oral presentation regarding our recent interesting study “Treatment characteristics and outcomes associated with sulphonylurea versus metformin therapy in incident type 2 diabetes mellitus patients: results of the German CREST study”. In this study, out

Lees meer

Welcome Ilse to Ingress-health!

Ingress-health welcomes Ilse as latest member of the team. Ilse will support health economic and outcomes research projects as junior researcher. She recently obtained a European Master’s degree in Health Economics and Management. This double degree program consists of a MSc in Health Economics, Policy and Law from the Erasmus University Rotterdam, NL and a

Lees meer

Can overall survival be improved in elderly multiple myeloma patients?

The ongoing introduction of novel therapies for MM provides clinicians and patients various treatment options in numerous lines of treatment. Understanding the current treatment practices and the corresponding outcomes in different age groups is of vital importance to understand whether these new treatments should be used in patients from all age groups and where options

Lees meer

Trial efficacy vs real world effectiveness in multiple myeloma

Real world evidence (RWE) is increasingly important in guiding reimbursement, but also treatment decisions, as HTAs, health insurers and clinicians are increasingly interested in the true real world (relative) effectiveness rather than the trials’ ideal (relative) efficacy. This requires combining and or comparing RWE effectiveness data with efficacy trial data. The primary aim of the

Lees meer